Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (217)	6/17/1999 4:23:00 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 523

I would like to know how NRGN got the WSJ to write such a prominent piece of fluff about the deal--it was like a press release. Given the WSJ's tendency to seek out the cloud that goes with any small-cap biotech's silver lining, I was surprised to see that they raised no negatives at all. After all, thus far, AIDD's chief claim to fame thus far is that it churns out replacement molecules quickly, to replace failed first (and sometimes second) generation molecules. AIDD may be a marvelous system, but NRGN's track record thus far suggests there are limits to the degree of optimization that AIDD can impart. Reality and virtual reality apparently do not have a 1:1 correspondence. There will be several neuro events 2H:99 that I would like Waldholtz to cover in a similarly uncritical fashion. NeuroInvestment (www.neuroinvestment.com)